Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
KBRA Assigns Preliminary Ratings to Gilead 2025-1 Aviation Limited
12:56pm, Friday, 07'th Feb 2025
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to the Series A Notes and Series B Notes issued by Gilead 2025-1 Aviation Limited and Gilead Aviation (Warehouse) LLC,
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:21am, Thursday, 06'th Feb 2025
Beyond analysts' top -and-bottom-line estimates for Gilead (GILD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
3 Top AI-Powered Biotech Stocks to Buy in February
09:45am, Thursday, 06'th Feb 2025
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-ch
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
06:55pm, Wednesday, 05'th Feb 2025
Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:05am, Tuesday, 04'th Feb 2025
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
07:00pm, Monday, 03'rd Feb 2025
In the most recent trading session, Gilead Sciences (GILD) closed at $98.38, indicating a +1.21% shift from the previous trading day.
Gilead: Strong Sales Growth Remains With Veklury And Beyond
04:56pm, Monday, 03'rd Feb 2025
Company sees strong growth in VEKLURY sales, driven by increased Covid-19 hospitalizations, with Q3 2024 sales up 9% to $692 million. LIVDELZI shows promise for long-term growth, with FDA Accelerated
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
03:31pm, Friday, 31'st Jan 2025
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Friday, 31'st Jan 2025
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Friday, 31'st Jan 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
08:00am, Thursday, 30'th Jan 2025
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
10:01am, Wednesday, 29'th Jan 2025
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
07:06pm, Tuesday, 28'th Jan 2025
In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
10:31am, Tuesday, 28'th Jan 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
5 Best CEFs This Month For Nearly 10% Yield (January 2025)
08:00am, Saturday, 25'th Jan 2025
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generall
